Full Press Release Details
BridgeBio Pharma Enters Into Agreement To Acquire Late Stage Therapy For Ultra-rare Disorder From Alexion; Launches Origin Biosciences To Develop And Commercialize Therapy.
BBIO
BridgeBio Pharma Enters Into Agreement To Acquire Late Stage Therapy For Ultra-rare Disorder From Alexion; Launches Origin Biosciences To Develop And Commercialize Therapy
Key Takeaway: BridgeBio Pharma Enters Into Agreement To Acquire Late Stage Therapy For Ultra-rare Disorder From Alexion; Launches Origin Biosciences To Develop And Commercialize Therapy